Haptoglobin blood assay to assess treatment compliance in rheumatoid arthitis patients treated with tocilizumab

Clin Exp Rheumatol. 2024 Jul;42(7):1516. doi: 10.55563/clinexprheumatol/ua2zfc. Epub 2024 May 1.

Authors

Pierre-Yves Montagnon¹, Marine Beauger¹, Marion Couderc¹, Anne Tournadre¹, Martin Soubrier¹, Sylvain Mathieu²

Affiliations

¹ Rheumatology Department, Gabriel Montpied Teaching Hospital, Clermont-Ferrand, France.
² Rheumatology Department, Gabriel Montpied Teaching Hospital, Clermont-Ferrand, France. [email protected].

PMID: 38757290
DOI: 10.55563/clinexprheumatol/ua2zfc

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized* / therapeutic use
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid* / blood
Arthritis, Rheumatoid* / drug therapy
Biomarkers* / blood
Female
Haptoglobins* / analysis
Humans
Male
Medication Adherence
Middle Aged
Predictive Value of Tests
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
tocilizumab
Haptoglobins
Biomarkers
Antirheumatic Agents
HP protein, human